This case suggests that serum thrombopoietin levels are primarily regulated by megakaryocyte mass rather than circulating platelet mass.
Answers are grounded in this paper and cite their sources.
No immediate change to Tpo assessment in thrombocytopenia; leaves open megakaryocyte mass as dominant regulator pending larger studies.
A patient with idiopathic thrombocytopenic purpura (ITP) developed T-cell lymphoma while undergoing steroid therapy. We examined the relationship between the patient's serum thrombopoietin (Tpo) level, platelet count, megakaryocyte number and CFU-Meg number during the second 5 d course of chemotherapy for lymphoma in which megakaryopoiesis switched from ITP phase to amegakaryocytic phase. The patient's platelet count was temporarily elevated but CFU-Meg numbers were markedly suppressed, and megakaryocyte numbers were decreased in this period, whereas serum Tpo level was not suppressed despite an increased platelet count, indicating that serum Tpo level is mainly regulated by megakaryocyte mass.
No takes yet. Share an insight, caveat, or question.
Nagasawa et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: